Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848583 | 0.76 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL24950489 | 0.76 | KDM4E (0.31) | CA1CA2 | |
| SCHEMBL13636034 | 0.76 | NOS3 (0.34) | CA1CA2NOS3NOS1NOS2 | |
| SCHEMBL25607104 | 0.76 | GABRA1 (0.30) | — | |
| SCHEMBL20122648 | 0.74 | GABRA1 (0.37) | CA1CA2 | |
| SCHEMBL25606946 | 0.71 | ALOX15 (0.31) | — | |
| SCHEMBL25607270 | 0.71 | — | — | |
| SCHEMBL6124129 | 0.71 | SMPD3 (0.35) | — | |
| SCHEMBL18699197 | 0.71 | ALDH1A1 (0.35) | — | |
| SCHEMBL19190921 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-09-09 | — | — | US | disclosed |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | ESKER THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2020-11-12 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| WO-2017007756-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | TYK2, JAK1, PDXK | CA1 4407/4885CA2 4329/4885NOS3 3608/4885 |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | CA1 4610/4885CA2 4725/4885NOS3 4088/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | CA1 4639/4885CA2 4751/4885NOS3 4046/4885 |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | CA1 4610/4885CA2 4725/4885NOS3 4088/4885 |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | CA1 262/4885CA2 582/4885NOS3 4121/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | CA1 3451/4885CA2 1978/4885NOS3 4599/4885 |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | CA1 262/4885CA2 582/4885NOS3 4121/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CA1 3255/4885CA2 4080/4885NOS3 3933/4885 |
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | CA1 262/4885CA2 582/4885NOS3 4121/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | CA1 3904/4885CA2 2262/4885NOS3 248/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | CA1 4429/4885CA2 4601/4885NOS3 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.